Denis Caillot

Dijon, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 139 publications

Unraveling the care pathway for CAR T-cell therapy in large B-cell lymphoma: insights from a nationwide study in France (2018-2023).

Unraveling the care pathway for CAR T-cell therapy in large B-cell lymphoma: insights from a nationwide study in France (2018-2023).

Journal: Leukemia & lymphoma

Published: April 29, 2026

Indirect treatment comparison of DVRd plus DR maintenance (PERSEUS study) versus DVTd or VTd with or without lenalidomide maintenance in transplant-eligible patients with previously untreated multiple myeloma.

Indirect treatment comparison of DVRd plus DR maintenance (PERSEUS study) versus DVTd or VTd with or without lenalidomide maintenance in transplant-eligible patients with previously untreated multiple myeloma.

Journal: Journal of medical economics

Published: February 17, 2026

FDG-PET medullary total tumor volume highlights high-risk patients with newly diagnosed multiple myeloma in CASSIOPEIA trial.

FDG-PET medullary total tumor volume highlights high-risk patients with newly diagnosed multiple myeloma in CASSIOPEIA trial.

Journal: Blood advances

Published: December 22, 2025

35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience.

35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience.

Journal: Blood cancer journal

Published: July 07, 2025

Poor Outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.

Poor Outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.

Journal: Blood advances

Published: June 30, 2025

Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.

Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.

Journal: Blood advances

Published: June 30, 2025

Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.

Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.

Journal: Blood advances

Published: June 30, 2025

Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial.

Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial.

Journal: Blood

Published: May 21, 2025

Real-World Utilization of Carfilzomib (Once or Twice Weekly) Initiated in Patients After a First Relapse Between 2017 and 2022 in France: An Analysis From a Large-Scale Epidemiology of Multiple MYeloma (EmmY) Cohort.

Real-World Utilization of Carfilzomib (Once or Twice Weekly) Initiated in Patients After a First Relapse Between 2017 and 2022 in France: An Analysis From a Large-Scale Epidemiology of Multiple MYeloma (EmmY) Cohort.

Journal: Clinical lymphoma, myeloma & leukemia

Published: April 18, 2025

Response profile and long-term outcomes in Cyclin D1-overexpressing multiple myeloma: insights from the CASSIOPEIA trial.

Response profile and long-term outcomes in Cyclin D1-overexpressing multiple myeloma: insights from the CASSIOPEIA trial.

Journal: Blood cancer journal

Published: April 05, 2025

Improving Advanced-Line Multiple Myeloma Care: Insights and Real-World Challenges from the EMMY Study.

Improving Advanced-Line Multiple Myeloma Care: Insights and Real-World Challenges from the EMMY Study.

Journal: Clinical hematology international

Published: March 18, 2025

Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results.

Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results.

Journal: Blood

Published: November 12, 2024

Showing 1-12 of 139

Last Updated: 09/26/2026